KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT (2016 - 2025)

Neogenomics (NEO) has disclosed EBT for 16 consecutive years, with -$12.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 23.08% year-over-year to -$12.4 million, compared with a TTM value of -$110.3 million through Dec 2025, down 36.68%, and an annual FY2025 reading of -$110.3 million, down 36.68% over the prior year.
  • EBT was -$12.4 million for Q4 2025 at Neogenomics, up from -$26.4 million in the prior quarter.
  • Across five years, EBT topped out at $73.4 million in Q2 2021 and bottomed at -$53.2 million in Q1 2022.
  • Average EBT over 5 years is -$23.1 million, with a median of -$25.6 million recorded in 2022.
  • Peak annual rise in EBT hit 508.98% in 2021, while the deepest fall reached 1142.75% in 2021.
  • Year by year, EBT stood at -$44.2 million in 2021, then surged by 42.26% to -$25.5 million in 2022, then surged by 40.11% to -$15.3 million in 2023, then decreased by 5.51% to -$16.1 million in 2024, then increased by 23.08% to -$12.4 million in 2025.
  • Business Quant data shows EBT for NEO at -$12.4 million in Q4 2025, -$26.4 million in Q3 2025, and -$45.8 million in Q2 2025.